Woodline Partners LP Krystal Biotech, Inc. Transaction History
Woodline Partners LP
- $11 Billion
- Q3 2024
A detailed history of Woodline Partners LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 179,815 shares of KRYS stock, worth $27.5 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
179,815
Previous 291,918
38.4%
Holding current value
$27.5 Million
Previous $53.6 Million
39.0%
% of portfolio
0.3%
Previous 0.54%
Shares
6 transactions
Others Institutions Holding KRYS
# of Institutions
309Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$604 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$436 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$401 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$222 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$151 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.92B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...